• A Clinical Case of Timely Diagnosis and Successful Treatment of Budd-Chiari Syndrome With Fulminant Cytolysis in the Setting of a First-time Diagnosed Myeloproliferative Disease
• A randomized, double-blind, placebo-controlled phase 3 study to assess efficacy and safety of ropeginterferon alfa-2b in patients with early/lower-risk primary myelofibrosis
• A Retrospective Longitudinal Study of Refugees With Eosinophilia at an Academic Center in the United States From 2015 to 2020
• Acute upper gastrointestinal bleeding due to portal hypertension in a patient with primary myelofibrosis: A case report
• Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature
• Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis Aged 70 Years or Older: A Study from the German Registry for Stem Cell Transplantation
• Analysis of risk factors for venous thromboembolism in patients with polycythemia vera and establishment of a prediction model
• Anterior Uveitis After Discontinuation of Janus Kinase Inhibitor, Ruxolitinib
• Anti-T-lymphocyte globulin improves GvHD-free and relapse-free survival in myelofibrosis after matched related or unrelated donor transplantation
• Applications of artificial intelligence to myeloproliferative neoplasms: a narrative review
• Assessment of Total Antioxidant Capacity, 8-Hydroxy-2'-deoxy-guanosine, the Genetic Landscape, and Their Associations in <em>BCR::ABL-1</em>-Negative Chronic and Blast Phase Myeloproliferative Neoplasms
• Autoimmune Myelofibrosis Revealing a Systemic Lupus Erythematosus
• Bone marrow fibrosis in newly diagnosed multiple myeloma and its correlation with clinicopathological factors
• C-Mannosyl tryptophan is a novel biomarker for thrombocytosis of myeloproliferative neoplasms
• Case report: Primary myelofibrosis presenting with portal hypertension mimicking cirrhosis
• Circulating Polymorphonuclear Myeloid-Derived Suppressor Cells (PMN-MDSCs) Have a Biological Role in Patients with Primary Myelofibrosis
• Clinical and Economic Implications of Hydroxyurea Intolerance in Polycythemia Vera in Routine Clinical Practice
• Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia
• Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study
• Combination Therapy with Ruxolitinib and Pegylated Interferon-alpha2a in Newly Diagnosed Patients with Polycythemia Vera
• Comparison of the crystal structures of the JAK1/2 inhibitor ruxolitinib and its hydrate and phosphate
• Congenital Dyserythropoietic Anemia Type II With Myelofibrosis in an Adult Patient: A Report of a Rare Case With a Brief Review
• Consistency of Spleen and Symptom Reduction Regardless of Cytopenia in Patients With Myelofibrosis Treated With Pacritinib
• Correction to "Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis"
• Crespiatico I, Zaghi M, Mastini C, et al. First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis. Blood. 2024;143(14):1399-1413
• Cross-tissue organization of myeloid cells in scleroderma and related fibrotic diseases
• Decision analysis for transplant candidates with primary myelofibrosis in the ruxolitinib era
• Delayed diagnosis of TAFRO syndrome: A case report
• Development and validation of an LC-MSMS method for the quantitation of pacritinib; application of kinetics in rabbits
• Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study
• Dysmorphic megakaryocytes in TAFRO syndrome: A case series from a single institute
• Endothelial LATS2 is a suppressor of bone marrow fibrosis
• Epidemiology and disease characteristics of myelofibrosis: a comparative analysis between Italy and global perspectives
• FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN)
• Histopathological Confirmed Polycythemia Vera with Transformation to Myelofibrosis Depicted on [(18)F]FDG PET/CT
• How I Treat Low-risk Polycythemia Vera Patients who Require Cytoreduction
• Identifying disease-modifying potential in myelofibrosis clinical trials
• IDH2 mutation accelerates TPO-induced myelofibrosis with enhanced S100a8/a9 and NFkappaB signaling in vivo
• Immunology and targeted therapy in Castleman disease
• Induction of remission after donor lymphocyte infusion following allogeneic transplant in a case of pediatric primary myelofibrosis
• Liver and spleen shear-wave elastography in the diagnosis and severity staging of myeloproliferative diseases and myelofibrosis
• Miliary TB and COVID-19 Coinfection in a Patient With a History of Post-polycythemia Vera Myelofibrosis Treated With Ruxolitinib: A Case Report
• Momelotinib - a promising advancement in the management of myelofibrosis in adults with anemia
• Momelotinib as first-line or second-line treatment following ruxolitinib in patients with primary or secondary myelofibrosis
• Momelotinib for the treatment of myelofibrosis
• Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2
• Momelotinib versus ruxolitinib in JAK inhibitor-naive patients with myelofibrosis: an efficacy/safety analysis in the Japanese subgroup of the phase 3 randomized SIMPLIFY-1 trial
• MoReLife - real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients
• Multi-omics differences in the bone marrow between essential thrombocythemia and prefibrotic primary myelofibrosis
• Myelofibrosis and allogeneic transplantation: critical points and challenges
• Myelofibrosis and anemia: A German claims data analysis to describe epidemiology and current treatment
• Myelofibrosis management in routine clinical practice with a focus on patients with cytopenias: recommendations from a global consensus group
• Myeloid sarcoma: Experience from a tertiary care center in southern India - A series of eight unusual cases
• Myeloproliferative Neoplasm Symptom Assessment Total Symptom Score (MPN-SAF TSS) in Chronic Myeloproliferative Neoplasms, Related with Genetic Burden, and Thrombosis
• Myeloproliferative neoplasms in the adolescent and young adult population: A comprehensive review of the literature
• Myeloproliferative Neoplasms Transcriptome Reveals Pro-Inflammatory Signature and Enrichment in Peripheral Blood Monocyte-Related Genes
• Myeloproliferative neoplasms: young patients, current data and future considerations
• Neuropilin2 in Mesenchymal Stromal Cells as a Potential Novel Therapeutic Target in Myelofibrosis
• Obliteration of liver sinusoids through platelet aggregates associated to extramedullary haematopoiesis in myeloid neoplasms
• Oral Decitabine/Cedazuridine Is an Effective Ambulatory Therapy for Patients With Myelofibrosis Refractory to JAK2 Inhibitor Therapy
• Overview of dyslipidemia and metabolic syndrome in myeloproliferative neoplasms
• Pachydermoperiostosis: Cosmetic implications in a multi-system genetic condition
• Pacritinib and concurrent azole antifungal therapy is deliverable in patients with hematologic malignancies
• Phase 1 Study of CK0801 in Treatment of Bone Marrow Failure Syndromes
• PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs: approval selpercatinib for solid tumor with RET fusion, gumarontinib for non-small cell lung cancer with MET gene exon 14 skipping mutation, momelotinib for my
• Population pharmacokinetics of imetelstat, a first-in-class oligonucleotide telomerase inhibitor
• Prognostic and Predictive Models in Myelofibrosis
• Proposals for Revised International Working Group-European LeukemiaNet Criteria for Anemia Response in Myelofibrosis
• Proteomic screening identifies PF4/Cxcl4 as a critical driver of myelofibrosis
• Pseudo-lymphocytosis caused by circulating megakaryocyte fragments in a patient with post-essential thrombocythemia myelofibrosis
• Quantitative analysis of bone marrow fibrosis highlights heterogeneity in myelofibrosis and augments histological assessment: An Insight from a phase II clinical study of zinpentraxin alfa
• Recent advances in JAK2 inhibition for the treatment of myelofibrosis
• Recent findings and advances in treatment of myeloproliferative neoplasms
• Red cell distribution width and prognosis in myelofibrosis patients treated with ruxolitinib
• Risk factors for ischemic stroke in patients with Philadelphia chromosome (Ph)-negative myeloproliferative neoplasms
• Ruxolitinib after fedratinib failure in patients with myelofibrosis: A real-world case series
• Ruxolitinib as a CaMKII Inhibitor for the Treatment of Cardiac Arrhythmias: Applications and Prospects
• Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: primary analysis of FREEDOM trial
• Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis
• Small molecule drug discovery targeting the JAK-STAT pathway
• Socio-demographic determinants of myelofibrosis outcomes in an underserved center and the SEER national database
• Successful pregnancy outcome in a patient with myelofibrosis receiving ruxolitinib treatment in the first trimester
• Successful ruxolitinib rechallenge after fedratinib failure in a patient with overt myelofibrosis
• Tacrolimus Treatment for TAFRO Syndrome
• TAFRO Syndrome on ¹⁸F-FDG-PET/CT: An Appealing Diagnostic Tool
• Targeting exhausted cytotoxic T cells through CTLA-4 inhibition promotes elimination of neoplastic cells in human myelofibrosis xenografts
• The Burden of symptoms and Quality of life of Filipino patients with Myeloproliferative neoplasm: A Multicenter Cross-sectional survey
• The characteristics of <em>CALR</em> mutations in myeloproliferative neoplasms: a clinical experience from a tertiary care center in Qatar and a literature review
• The clinical significance of TAT, PIC, TM, and t-PAIC in vascular events of BCR/ABL-negative myeloproliferative neoplasms
• The Gordian knot: ruxolitinib or transplants for high-risk myelofibrosis
• The Variation in the Traits Ameliorated by Inhibitors of JAK1/2, TGF-beta, P-Selectin, and CXCR1/CXCR2 in the Gata1(low) Model Suggests That Myelofibrosis Should Be Treated by These Drugs in Combination
• Top Ten Tips Palliative Care Clinicians Should Know About Caring for Patients with Myeloproliferative Neoplasms
• Transfusion-related cost offsets and time burden in patients with myelofibrosis on momelotinib vs. danazol from MOMENTUM
• Translation, Cultural Adaptation, and Validation into Romanian of the Myeloproliferative Neoplasm Symptom Assessment Form-Total Symptom Score (MPN-SAF TSS or MPN-10) Questionnaire
• Treatment of myelofibrosis with refractory anemia with luspatercept: a multicenter Chinese study
• Type II mode of JAK2 inhibition and destabilization are potential therapeutic approaches against the ruxolitinib resistance driven myeloproliferative neoplasms
• Unprovoked Atypical Absence Status Epilepticus in a Patient With Allogeneic Stem Cell Transplantation
• Venous Stasis Ulceration due to Massive Splenomegaly Causing Iliac Vein Compression From Secondary Myelofibrosis
• Vitamin B12 Deficiency Manifesting As Pancytopenia, Lymphadenopathy, and Fever: A Clinical Mimic of Hematologic Malignancies
• Would you like to take some more ruxolitinib after your fedratinib?